Friday, December 16, 2011

Aalto University researchers demonstrate an almost noiseless nanomechanical microwave amplifier

Aalto University researchers demonstrate an almost noiseless nanomechanical microwave amplifier [ Back to EurekAlert! ] Public release date: 15-Dec-2011
[ | E-mail | Share Share ]

Contact: Tero Heikkila
Tero.Heikkila@aalto.fi
358-947-022-396
Aalto University

Physicists in Aalto University, Finland, have shown how a nanomechanical oscillator can be used for detection and amplification of feeble radio waves or microwaves. A measurement using such a tiny device, resembling a miniaturized guitar string, can be performed with the least possible disturbance. The results were recently published in the most prestigious scientific arena, the British journal Nature.

The researchers cooled the nanomechanical oscillator, thousand times thinner than a human hair, down to a low temperature near the absolute zero at -273 centigrade. Under such extreme conditions, even nearly macroscopic sized objects follow the laws of quantum physics which often contradict common sense. In the Low Temperature Laboratory experiments, the nearly billion atoms comprising the nanomechanical resonator were oscillating in pace in their shared quantum state.

The scientists had fabricated the device in contact with a superconducting cavity resonator, which exchanges energy with the nanomechanical resonator. This allowed amplification of their resonant motion. This is very similar to what happens in a guitar, where the string and the echo chamber resonate at the same frequency. Instead of the musician playing the guitar string, the energy source was provided by a microwave laser.

Microwaves get amplified by interaction of quantum oscillations

Researchers from the Low Temperature Laboratory, Aalto University, have shown how to detect and amplify electromagnetic signals almost noiselessly using a guitar-string like mechanical vibrating wire. In the ideal case the method adds only the minimum amount of noise required by quantum mechanics.

The presently used semiconductor transistor amplifiers are complicated and noisy devices, and operate far away from a fundamental disturbance limit set by quantum physics. The Low Temperature Laboratory scientists showed that by taking advantage of the quantum resonant motion, injected microwave radiation can be amplified with little disturbance. The principle hence allows for detecting much weaker signals than usually.

Any measurement method or device always adds some disturbance. Ideally, all the noise is due vacuum fluctuations predicted by quantum mechanics. In theory, our principle reaches this fundamental limit. In the experiment, we got very close to this limit, says Dr. Francesco Massel.

The discovery was actually quite unexpected. We were aiming to cool the nanomechanical resonator down to its quantum ground state. The cooling should manifest as a weakening of a probing signal, which we observed. But when we slightly changed the frequency of the microwave laser, we saw the probing signal to strengthen enormously. We had created a nearly quantum limited microwave amplifier, says Academy Research Fellow Mika Sillanp who planned the project and made the measurements.

Certain real-life applications will benefit from the better amplifier based on the new Aalto method, but reaching this stage requires more research effort. Most likely, the mechanical microwave amplifier will be first applied in related basic research, which will further expand our knowledge of the borderline between the everyday world and the quantum realm.

According to Academy Research Fellow Tero Heikkil, the beauty of the amplifier is in its simplicity: it consists of two coupled oscillators. Therefore, the same method can be realized in basically any media. By using a different structure of the cavity, one could detect terahertz radiation which would also be a major application.

###

The research was carried out in the Low Temperature Laboratory, which belongs to the Aalto University School of Science, and is part of the Centre of Excellence in Low Temperature Quantum Phenomena and Devices of the Finnish Academy. The devices used in the measurements were fabricated by VTT Nanotechnologies and microsystems. The research was funded by the Finnish Academy, European Research Council ERC, and the European Union.



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Aalto University researchers demonstrate an almost noiseless nanomechanical microwave amplifier [ Back to EurekAlert! ] Public release date: 15-Dec-2011
[ | E-mail | Share Share ]

Contact: Tero Heikkila
Tero.Heikkila@aalto.fi
358-947-022-396
Aalto University

Physicists in Aalto University, Finland, have shown how a nanomechanical oscillator can be used for detection and amplification of feeble radio waves or microwaves. A measurement using such a tiny device, resembling a miniaturized guitar string, can be performed with the least possible disturbance. The results were recently published in the most prestigious scientific arena, the British journal Nature.

The researchers cooled the nanomechanical oscillator, thousand times thinner than a human hair, down to a low temperature near the absolute zero at -273 centigrade. Under such extreme conditions, even nearly macroscopic sized objects follow the laws of quantum physics which often contradict common sense. In the Low Temperature Laboratory experiments, the nearly billion atoms comprising the nanomechanical resonator were oscillating in pace in their shared quantum state.

The scientists had fabricated the device in contact with a superconducting cavity resonator, which exchanges energy with the nanomechanical resonator. This allowed amplification of their resonant motion. This is very similar to what happens in a guitar, where the string and the echo chamber resonate at the same frequency. Instead of the musician playing the guitar string, the energy source was provided by a microwave laser.

Microwaves get amplified by interaction of quantum oscillations

Researchers from the Low Temperature Laboratory, Aalto University, have shown how to detect and amplify electromagnetic signals almost noiselessly using a guitar-string like mechanical vibrating wire. In the ideal case the method adds only the minimum amount of noise required by quantum mechanics.

The presently used semiconductor transistor amplifiers are complicated and noisy devices, and operate far away from a fundamental disturbance limit set by quantum physics. The Low Temperature Laboratory scientists showed that by taking advantage of the quantum resonant motion, injected microwave radiation can be amplified with little disturbance. The principle hence allows for detecting much weaker signals than usually.

Any measurement method or device always adds some disturbance. Ideally, all the noise is due vacuum fluctuations predicted by quantum mechanics. In theory, our principle reaches this fundamental limit. In the experiment, we got very close to this limit, says Dr. Francesco Massel.

The discovery was actually quite unexpected. We were aiming to cool the nanomechanical resonator down to its quantum ground state. The cooling should manifest as a weakening of a probing signal, which we observed. But when we slightly changed the frequency of the microwave laser, we saw the probing signal to strengthen enormously. We had created a nearly quantum limited microwave amplifier, says Academy Research Fellow Mika Sillanp who planned the project and made the measurements.

Certain real-life applications will benefit from the better amplifier based on the new Aalto method, but reaching this stage requires more research effort. Most likely, the mechanical microwave amplifier will be first applied in related basic research, which will further expand our knowledge of the borderline between the everyday world and the quantum realm.

According to Academy Research Fellow Tero Heikkil, the beauty of the amplifier is in its simplicity: it consists of two coupled oscillators. Therefore, the same method can be realized in basically any media. By using a different structure of the cavity, one could detect terahertz radiation which would also be a major application.

###

The research was carried out in the Low Temperature Laboratory, which belongs to the Aalto University School of Science, and is part of the Centre of Excellence in Low Temperature Quantum Phenomena and Devices of the Finnish Academy. The devices used in the measurements were fabricated by VTT Nanotechnologies and microsystems. The research was funded by the Finnish Academy, European Research Council ERC, and the European Union.



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-12/au-aur121511.php

evelyn lauder nfl standings devin hester devin hester shayne lamas cain velasquez dos santos

Wednesday, December 7, 2011

Balloon Juice ? Breast Cancer, PPACA, and a Change of Heart ...

Obamacares.


LA Times featured an op-ed yesterday that is a must-read:
I want to apologize to President Obama. But first, some background.

I found out three weeks ago I have cancer. I?m 49 years old, have been married for almost 20 years and have two kids. My husband has his own small computer business, and I run a small nonprofit in the San Fernando Valley. I am also an artist. Money is tight, and we don?t spend it frivolously. We?re just ordinary, middle-class people, making an honest living, raising great kids and participating in our community, the kids? schools and church.

We?re good people, and we work hard. But we haven?t been able to afford health insurance for more than two years. And now I have third-stage breast cancer and am facing months of expensive treatment.

To understand how such a thing could happen to a family like ours, I need to take you back nine years to when my husband got laid off from the entertainment company where he?d worked for 10 years. Until then, we had been insured through his work, with a first-rate plan. After he got laid off, we got to keep that health insurance for 18 months through COBRA, by paying $1,300 a month, which was a huge burden on an unemployed father and his family.

By the time the COBRA ran out, my husband had decided to go into business for himself, so we had to purchase our own insurance. That was fine for a while. Every year his business grew. But insurance premiums were steadily rising too. More than once, we switched carriers for a lower rate, only to have them raise rates significantly after a few months.

snip

Fortunately for me, I?ve been saved by the federal government?s Pre-existing Condition Insurance Plan, something I had never heard of before needing it. It?s part of President Obama?s healthcare plan, one of the things that has already kicked in, and it guarantees access to insurance for U.S. citizens with preexisting conditions who have been uninsured for at least six months. The application was short, the premiums are affordable, and I have found the people who work in the administration office to be quite compassionate (nothing like the people I have dealt with over the years at other insurance companies.) It?s not perfect, of course, and it still leaves many people in need out in the cold. But it?s a start, and for me it?s been a lifesaver ? perhaps literally.

Which brings me to my apology. I was pretty mad at Obama before I learned about this new insurance plan. I had changed my registration from Democrat to Independent, and I had blacked out the top of the ?h? on my Obama bumper sticker, so that it read, ?Got nope? instead of ?got hope.? I felt like he had let down the struggling middle class. My son and I had campaigned for him, but since he took office, we felt he had let us down.

So this is my public apology. I?m sorry I didn?t do enough of my own research to find out what promises the president has made good on. I?m sorry I didn?t realize that he really has stood up for me and my family, and for so many others like us. I?m getting a new bumper sticker to cover the one that says ?Got nope.? It will say ?ObamaCares.?

(read the rest)


As more and more people find out about the benefits of the Patient Protection and Affordable Care Act, Republicans are going to find it difficult to continue the ?Repeal Obaaaaahmaacare? siren song. And the fact that health insurers are cutting their lobbying costs because the Department of Health and Human Services has stated that such lobbying costs cannot be counted as providing healthcare is just icing on the cake.

From The People?s View,

Their lobbying scheme didn?t work. They know it and are finally resigning to the fact that health reform is the law of the land and that they are going to have to comply with it. And since they can?t count lobbying costs as providing you with health care, lobbying costs are now in direct competition with shareholder gain. If the insurance companies want to make more money but can?t do it by kicking people off their insurance or counting everything and its mother as a ?health care cost,? there are only a few ways of doing it: cut administrative costs (hello, industry lobbyists, hi! Waving atcha!), and raise revenue by attracting more customers in a level playing field.

As many of you know, I have a microprolactinoma (a pituitary tumor). Navigating the health insurance industry over the past 6 years has been a pain in the ass. I?ve wrangled with Blue Shield and I?ve been horrified by Kaiser Permanente, and the experience has left me disheartened, frustrated, and often in tears. I have found myself calculating how much time I will allow for the drugs to work and shrink the damn thing in my brain before I decide to have it surgically removed just so the procedure will be covered by insurance. It?s insane.

No one should be forced to make a significant health decision that includes life-threatening surgery simply because they don?t have the time to let non-surgical options run their course, and they won?t be able to pay for surgery should they need it. So I am very grateful to President Obama for the government?s pre-existing condition insurance plan because when my COBRA runs out, I?m going to need it.

[cross-posted at Angry Black Lady Chronicles]

December 6, 2011 1:29 pm Posted?in:?World's Best Healthcare (If You Can Afford It) ?41 Comments


Source: http://www.balloon-juice.com/2011/12/06/breast-cancer-ppaca-and-a-change-of-heart-about-president-obama/

packers stock mastectomy st. nicholas st. nicholas heisman finalists heisman finalists kepler 22 b

Tuesday, December 6, 2011

Contemporary art world turns to Turner Prize (Reuters)

LONDON (Reuters) ? Britain's Turner Prize, one of the world's top contemporary art honors, is awarded later on Monday, and for only the second time in its 27-year history the ceremony will be held outside London.

The host in 2011 is the BALTIC gallery in Gateshead, northern England, where celebrity photographer Mario Testino will present the prize.

The move outside the capital has been welcomed, both for underlining that it is a national, not London honor and for the quality of the space dedicated to the Turner show.

"The Baltic in Gateshead has had its ups and downs, but the Turner looks happier there than it ever has in the tomb-like Tate Britain," said Charles Darwent, writing in the Independent on Sunday newspaper.

"Of course, the Tate is still behind the prize, but you wouldn't necessarily guess it. I can't recall a stronger show over the past 27 years, better chosen, better displayed, more poised or grown-up."

The four nominees for the award, which comes with a 25,000 pound cheque and contemporary art celebrity status in Britain and beyond, are Karla Black, Martin Boyce, Hilary Lloyd and George Shaw.

Glasgow-based Boyce, whose sculptural installation combines the outside feel of a park with interior design and high modernism, is the bookmakers' favorite.

He is closely followed by Shaw, the only painter among the nominees, who evokes bleak urban landscapes of crumbling buildings and wasteland in small, detailed images.

A long way behind in terms of betting odds, but popular among the critics, is Black, whose fragile installations involve see-through cellophane "curtains" and huge mounds of paper colored in powdered paint.

Finally, Lloyd's room of video works deliberately draws the viewer's gaze to the technology she uses as well as the images they project.

Whoever wins the prize, some in the art world feel 2011 has helped put the Turner Prize back on the cultural map.

In the past it has been dismissed as "emperor's new clothes," and previous winners include Martin Creed, whose exhibit in 2001 was an empty room with lights going on and off.

Three years earlier Chris Ofili triumphed with paintings propped up on elephant dung.

But it has also helped launch the careers of some of Britain's leading contemporary artists, including Damien Hirst, who won in 1995, Steve McQueen (1999) and Antony Gormley (1994).

Richard Dorment of the Telegraph wrote of this year's show: "Here's a turn up. Just when I thought the Turner Prize couldn't get more irrelevant if it tried, bingo, along comes a first-class shortlist and an exhibition as good as any I've seen in two decades of reviewing the event."

(Reporting by Mike Collett-White, editing by Paul Casciato)

Source: http://us.rd.yahoo.com/dailynews/rss/tv/*http%3A//news.yahoo.com/s/nm/20111205/stage_nm/us_turnerprize

kim kardashian ghost hunters honda generator honda generator cc sabathia ruth madoff ruth madoff

Monday, December 5, 2011

Republican Presidential Candidates on U.S. Health Care Coverage (ContributorNetwork)

According to a recent Gallup poll, three out of four Americans believe U.S. health care coverage has major problems or is in crisis. When asked what the most urgent health problem facing the country is, most Americans name access and costs, far ahead of both cancer and obesity. Others, however, believe the greatest problems facing health care are actually government interference and the size of the government's health care budget.

For these reasons, the candidates seeking the Republican presidential nomination were asked what about their views of U.S. health care coverage.

Here is what they said, according to the CNN-Tea Party debate transcript:

* Mitt Romney: "I'd reform Medicare and reform Medicaid and reform Social Security to get them on a sustainable basis, not for current retirees, but for those in their 20s and 30s and early 50s. But the key to balancing the budget -- and we talk about all the waste in government and the inefficiency. And having spent 25 years in business, I know something about taking waste out of enterprises. I'd love to do that to the federal government. And there is massive waste. But we're not going to balance the budget just by pretending that all we have to do is take out the waste. We're going to have to cut spending. And I'm in favor of cutting spending, capping federal spending as a percentage of GDP, at 20 percent or less, and having a balanced budget amendment. That's essential to rein in the scale of the federal government. ... The right answer for America is to stop the growth of the federal government and to start the growth of the private sector."

* Newt Gingrich: "Anybody who knows anything about the federal government knows that there's such an enormous volume of waste, that if you simply had a serious all-out effort to modernize the federal government, you would have hundreds of billions of dollars of savings falling off. ? The federal government is such a bad manager of money, that somewhere between $70 billion and $120 billion a year in Medicare and Medicaid is paid to crooks. We wrote a book several years ago called "Stop Paying the Crooks." I thought it was pretty obvious even for Washington. So I would start to balance the budget by stop paying the crooks, not by cheating honest Americans."

* Rick Santorum: "The idea that unless we have a government-run, one-size-fits-all Medicare program, that that's throwing grandma off a cliff, is Washington think -- is people who think in Washington this president, who believes that they know better than you how to run your life and how to purchase your health care. I trust you, I trust the American people. That is the greatness of our country."

* Ron Paul: "In a society that you accept welfarism and socialism, he (a young person with no health insurance) expects the government to take care of him. ? But what he should do is whatever he wants to do, and assume responsibility for himself. My advice to him would be to have a major medical policy."

CNN debate moderator Wolf Blitzer then asked Paul a follow-up question: Should society just allow a person with no health insurance to die?

* Paul: "That's what freedom is all about, taking your own risks. This whole idea that you have to prepare and take care of everybody."

Source: http://us.rd.yahoo.com/dailynews/rss/gop/*http%3A//news.yahoo.com/s/ac/20111206/pl_ac/10607141_republican_presidential_candidates_on_us_health_care_coverage

uppity uppity stuffing brandon mcinerney brandon mcinerney black friday 2011 deals nfl power rankings week 12

Will Wow (TIME)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories Stories, News Feeds and News via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/169475772?client_source=feed&format=rss

lsu football lsu football miguel cotto vs antonio margarito terminator salvation terminator salvation rockefeller center how the grinch stole christmas

Sunday, December 4, 2011

Amazon Announces Holiday Daily Deals Site, ?Flurry Deals?

amazon-daily-dealsIt's Cyber Monday all month long, at least according to Amazon, which announced its new holiday deals vertical this morning, residing at www.amazon.com/flurrydeals. The site currently features decently discounted items as an extension of the Cyber Monday promotion. But starting this Sunday, Amazon will begin offering category-specific daily deals. It's even providing an email sign-up form so shoppers won't miss the sales.

Source: http://feedproxy.google.com/~r/Techcrunch/~3/_I9opy5ERl0/

cliff lee the raven the raven lawrence o donnell fresno state fresno state psa test

Saturday, December 3, 2011

New child-adapted Chagas disease treatment approved for registration

New child-adapted Chagas disease treatment approved for registration [ Back to EurekAlert! ] Public release date: 2-Dec-2011
[ | E-mail | Share Share ]

Contact: Oliver Yun
oyun@dndi.org
646-266-5216
Drugs for Neglected Diseases Initiative

This release is available in Portuguese and Spanish.

Rio de Janeiro and Recife, Brazil, and Geneva, Switzerland 2 December 2011 -- Today, at the occasion of the 4th DNDi Partners' Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi). Registration of this child-adapted formulation of benznidazole will be published on 12 December 2011.

This new tablet means easier-to-administer and safer treatment of Chagas disease in infants and young children under the age of two, as they will receive accurate dosage.

Until today, benznidazole was available only as a 100-mg tablet for adults. Treatment for young children required cutting adult pills into tiny slivers up to 12 pieces depending on the child's weight and crushing and mixing them with water or juice, to be administered twice a day for 60 days. This difficult and inefficient method often results in improper dosing, risks of increased side-effects or ineffective treatment, and treatment stoppages.

Chagas disease infects an estimated 8 to 10 million people, mostly in Latin America, and kills some 12,000 people each year, making it the leading parasitic killer in the Americas, where it causes more deaths than malaria. The Chagas parasite is primarily transmitted via the bite of the blood-sucking triatome bug, widely known as the 'kissing bug', which is often found in poor housing conditions. In addition to blood transfusion, organ transplant, or ingesting infected food, the parasite is also transmitted during pregnancy from mother to child.

This new dosage form for children represents real progress for several reasons. Children are at especially high risk of infection, with a majority of them born from infected mothers. It is known that early treatment using benznidazole in the first year of life can eliminate the parasite in more than 90% of infected newborns. Thus, babies infected with Chagas disease will benefit the most from this new paediatric tablet.

'Thousands of mothers with Chagas disease-infected babies will welcome this as more than just a pill', says Manuel Gutirrez, President of the International Federation of Chagas Patients. 'Their voices have finally been heard.'

The new 12.5-mg tablet is easily dispersible (disintegrated) and adapted for babies and children up to two years of age (20 kg body weight). Treatment is designed to use one, two, or three tablets, depending on weight (recommended dosage, 5-10 mg/kg bodyweight/day).

'The presentation of this paediatric dosage form of benznidazole, as a final result of the collaborative project between DNDi and LAFEPE, opens possibilities for effective treatment [] for thousands of children', says Dr Mirta Roses Periago, Director of the Pan American Health Organization (PAHO). 'From now on, hope of an early cure for infection of the parasite that causes Chagas disease is a wonderful reality.'

Tools to facilitate implementation of and access to the new treatment include a Demand Forecast, a Procurement Guide, and a Tool Box providing training and educational materials for doctors, other health professionals, mothers, and caregivers regarding appropriate use of the treatment.

In 2008, DNDi and LAFEPE entered a joint development agreement for this dosage form. The new tablet will be produced by LAFEPE, a public pharmaceutical manufacturer run by the State of Pernambuco in Brazil and the sole global producer of benznidazole.

'We will exert all efforts, regarding commercial aspects, towards rapid patient access of this drug', says Luciano Vasquez, President of LAFEPE. 'It will be offered at cost to all public health institutions, including the Ministry of Health of Brazil.' Indeed, the paediatric dosage form will also be made available at cost to non-governmental organizations and philanthropic institutions.

The new paediatric dosage form has been granted registration from Brazil's National Health Surveillance Agency (ANVISA), and DNDi is collaborating with LAFEPE to make the drug widely available, notably by working to register the drug in Argentina, Bolivia, Colombia, and Paraguay priority countries where Chagas disease prevalence is high and treatment is urgently needed.

'At a time when efforts are being made to secure production of benznidazole, we must ensure that this new product is made available in all endemic areas and that treatment of children is rapidly expanded, in addition to the treatment of adults', says Dr Bernard Pcoul, Executive Director of DNDi. 'With this new tablet, we can reach a turning point for the treatment of children infected with Chagas disease and we have to move rapidly to get the drug to them.'

###

The project received funding support from the Department for International Development (DFID), UK; the Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Mdecins Sans Frontires/Doctors without Borders (International, Italy, Brazil); the Spanish Agency for International Development Cooperation (AECID), Spain; the Swiss Agency for Development and Cooperation (SDC), Switzerland; the United States Agency for International Development, via the 4th Sector Health Project implemented by Abt Associates, Inc.; Swiss private foundations and individual donors.

About Chagas Disease

Chagas disease (American trypanosomiasis) infects an estimated 8 to 10 million people, mostly in Latin America, where it is endemic in 21 countries. It kills some 12,000 people each year, making it the leading parasitic killer in the Americas. The people most affected by the disease are very poor and live in inadequate housing conditions and often have little access to healthcare. Cases are also rising in North America, Europe, Japan, and Australia. Caused by the parasite Trypanosoma cruzi, Chagas disease starts with an early, acute stage lasting about two months, and is followed by a late, chronic stage lasting through lifetime, in which up to 30% of patients develop heart damage and up to 10% may have severe damage to their digestive system. In early adulthood, patients with these symptoms ultimately die, usually from heart damage. The Chagas parasite is primarily transmitted via the bite of the blood-sucking triatome bug, sometimes called the 'kissing bug'. Chagas is also transmitted by blood transfusion, organ transplantation, oral ingestion, or during pregnancy from mother to newborn. The latter, congenital Chagas disease, is considered to represent the most important mode of transmission of the coming years, and it is estimated that over 14,000 new such cases occur annually.

About LAFEPE

Pernambuco State Pharmaceutical Laboratory (Laboratrio Farmacutico do Estado de Pernambuco; LAFEPE) is the second largest public laboratory in Brazil. LAFEPE was created in 1966 to produce medicines at low cost for people with limited purchasing power. Based in Recife, the capital of the state of Pernambuco in northeastern Brazil, LAFEPE focuses on developing, producing, and marketing drugs to support the needs of public health policy. For example, in 1994, it became the first official laboratory in Brazil to produce the antiretroviral zidovudine (AZT). The Pernambuco laboratory invests in the modernization of its facilities, with high-tech industrial equipment. Its pioneering programme, 'Popular Pharmacy', set up in popular market areas in different regions of the state, serves as a model for the federal government. www.lafepe.pe.gov.br

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, and paediatric HIV. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council for Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The Special Programme for Tropical Disease Research (TDR) serves as a permanent observer. Since 2003, DNDi has delivered five new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, and a set of combination therapies for visceral leishmaniasis in Asia. The new paediatric dosage form of benznidazole is now the sixth treatment delivered by DNDi since its inception eight years ago. www.dndi.org

Media contacts:
DNDi Latin America, Rio de Janeiro (Spanish, Portuguese, English): Flavio Pontes (on site)
office: +55 21 2215 2941 / mobile: +55 21 8123 4133 / email: press@dndi.org.br

DNDi International, Geneva (French, English): Violaine Dllenbach
office: +41 22 906 92 47 / mobile: +41 79 424 14 74 / email: vdallenbach@dndi.org

DNDi North America, New York (English): Oliver Yun
office: +1-646-616-8681 / mobile: +1-646-266-5216 / email: oyun@dndi.org


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


New child-adapted Chagas disease treatment approved for registration [ Back to EurekAlert! ] Public release date: 2-Dec-2011
[ | E-mail | Share Share ]

Contact: Oliver Yun
oyun@dndi.org
646-266-5216
Drugs for Neglected Diseases Initiative

This release is available in Portuguese and Spanish.

Rio de Janeiro and Recife, Brazil, and Geneva, Switzerland 2 December 2011 -- Today, at the occasion of the 4th DNDi Partners' Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi). Registration of this child-adapted formulation of benznidazole will be published on 12 December 2011.

This new tablet means easier-to-administer and safer treatment of Chagas disease in infants and young children under the age of two, as they will receive accurate dosage.

Until today, benznidazole was available only as a 100-mg tablet for adults. Treatment for young children required cutting adult pills into tiny slivers up to 12 pieces depending on the child's weight and crushing and mixing them with water or juice, to be administered twice a day for 60 days. This difficult and inefficient method often results in improper dosing, risks of increased side-effects or ineffective treatment, and treatment stoppages.

Chagas disease infects an estimated 8 to 10 million people, mostly in Latin America, and kills some 12,000 people each year, making it the leading parasitic killer in the Americas, where it causes more deaths than malaria. The Chagas parasite is primarily transmitted via the bite of the blood-sucking triatome bug, widely known as the 'kissing bug', which is often found in poor housing conditions. In addition to blood transfusion, organ transplant, or ingesting infected food, the parasite is also transmitted during pregnancy from mother to child.

This new dosage form for children represents real progress for several reasons. Children are at especially high risk of infection, with a majority of them born from infected mothers. It is known that early treatment using benznidazole in the first year of life can eliminate the parasite in more than 90% of infected newborns. Thus, babies infected with Chagas disease will benefit the most from this new paediatric tablet.

'Thousands of mothers with Chagas disease-infected babies will welcome this as more than just a pill', says Manuel Gutirrez, President of the International Federation of Chagas Patients. 'Their voices have finally been heard.'

The new 12.5-mg tablet is easily dispersible (disintegrated) and adapted for babies and children up to two years of age (20 kg body weight). Treatment is designed to use one, two, or three tablets, depending on weight (recommended dosage, 5-10 mg/kg bodyweight/day).

'The presentation of this paediatric dosage form of benznidazole, as a final result of the collaborative project between DNDi and LAFEPE, opens possibilities for effective treatment [] for thousands of children', says Dr Mirta Roses Periago, Director of the Pan American Health Organization (PAHO). 'From now on, hope of an early cure for infection of the parasite that causes Chagas disease is a wonderful reality.'

Tools to facilitate implementation of and access to the new treatment include a Demand Forecast, a Procurement Guide, and a Tool Box providing training and educational materials for doctors, other health professionals, mothers, and caregivers regarding appropriate use of the treatment.

In 2008, DNDi and LAFEPE entered a joint development agreement for this dosage form. The new tablet will be produced by LAFEPE, a public pharmaceutical manufacturer run by the State of Pernambuco in Brazil and the sole global producer of benznidazole.

'We will exert all efforts, regarding commercial aspects, towards rapid patient access of this drug', says Luciano Vasquez, President of LAFEPE. 'It will be offered at cost to all public health institutions, including the Ministry of Health of Brazil.' Indeed, the paediatric dosage form will also be made available at cost to non-governmental organizations and philanthropic institutions.

The new paediatric dosage form has been granted registration from Brazil's National Health Surveillance Agency (ANVISA), and DNDi is collaborating with LAFEPE to make the drug widely available, notably by working to register the drug in Argentina, Bolivia, Colombia, and Paraguay priority countries where Chagas disease prevalence is high and treatment is urgently needed.

'At a time when efforts are being made to secure production of benznidazole, we must ensure that this new product is made available in all endemic areas and that treatment of children is rapidly expanded, in addition to the treatment of adults', says Dr Bernard Pcoul, Executive Director of DNDi. 'With this new tablet, we can reach a turning point for the treatment of children infected with Chagas disease and we have to move rapidly to get the drug to them.'

###

The project received funding support from the Department for International Development (DFID), UK; the Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Mdecins Sans Frontires/Doctors without Borders (International, Italy, Brazil); the Spanish Agency for International Development Cooperation (AECID), Spain; the Swiss Agency for Development and Cooperation (SDC), Switzerland; the United States Agency for International Development, via the 4th Sector Health Project implemented by Abt Associates, Inc.; Swiss private foundations and individual donors.

About Chagas Disease

Chagas disease (American trypanosomiasis) infects an estimated 8 to 10 million people, mostly in Latin America, where it is endemic in 21 countries. It kills some 12,000 people each year, making it the leading parasitic killer in the Americas. The people most affected by the disease are very poor and live in inadequate housing conditions and often have little access to healthcare. Cases are also rising in North America, Europe, Japan, and Australia. Caused by the parasite Trypanosoma cruzi, Chagas disease starts with an early, acute stage lasting about two months, and is followed by a late, chronic stage lasting through lifetime, in which up to 30% of patients develop heart damage and up to 10% may have severe damage to their digestive system. In early adulthood, patients with these symptoms ultimately die, usually from heart damage. The Chagas parasite is primarily transmitted via the bite of the blood-sucking triatome bug, sometimes called the 'kissing bug'. Chagas is also transmitted by blood transfusion, organ transplantation, oral ingestion, or during pregnancy from mother to newborn. The latter, congenital Chagas disease, is considered to represent the most important mode of transmission of the coming years, and it is estimated that over 14,000 new such cases occur annually.

About LAFEPE

Pernambuco State Pharmaceutical Laboratory (Laboratrio Farmacutico do Estado de Pernambuco; LAFEPE) is the second largest public laboratory in Brazil. LAFEPE was created in 1966 to produce medicines at low cost for people with limited purchasing power. Based in Recife, the capital of the state of Pernambuco in northeastern Brazil, LAFEPE focuses on developing, producing, and marketing drugs to support the needs of public health policy. For example, in 1994, it became the first official laboratory in Brazil to produce the antiretroviral zidovudine (AZT). The Pernambuco laboratory invests in the modernization of its facilities, with high-tech industrial equipment. Its pioneering programme, 'Popular Pharmacy', set up in popular market areas in different regions of the state, serves as a model for the federal government. www.lafepe.pe.gov.br

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, and paediatric HIV. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council for Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The Special Programme for Tropical Disease Research (TDR) serves as a permanent observer. Since 2003, DNDi has delivered five new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, and a set of combination therapies for visceral leishmaniasis in Asia. The new paediatric dosage form of benznidazole is now the sixth treatment delivered by DNDi since its inception eight years ago. www.dndi.org

Media contacts:
DNDi Latin America, Rio de Janeiro (Spanish, Portuguese, English): Flavio Pontes (on site)
office: +55 21 2215 2941 / mobile: +55 21 8123 4133 / email: press@dndi.org.br

DNDi International, Geneva (French, English): Violaine Dllenbach
office: +41 22 906 92 47 / mobile: +41 79 424 14 74 / email: vdallenbach@dndi.org

DNDi North America, New York (English): Oliver Yun
office: +1-646-616-8681 / mobile: +1-646-266-5216 / email: oyun@dndi.org


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-12/dfnd-ncc120211.php

occupy san francisco occupy san francisco top chef just desserts jamarcus russell sister wives st louis weather jack the cat